Age >= years at the NCI clinical center (>= years at other participating sites) Medulloblastoma:\r\n* Posterior fossa classic, desmoplastic or extensive nodular or anaplastic/large cell medulloblastoma with appropriate and sufficient tumor material (FFPE or snap frozen) for proposed assays: all stages, age less than years at diagnosis\r\n* Posterior fossa classic or anaplastic/large cell medulloblastoma with sufficient tumor material (FFPE or snap frozen) for proposed assays: clinically high-stage (neuraxis or extra-neural dissemination, M-), age greater than years to less than years at diagnosis\r\n* Posterior fossa medulloblastoma, those years of age and above at diagnosis, will only be eligible if they have evidence of neuraxis or extraneural dissemination. Patients years of age and above with low-stage (standard-risk, M) medulloblastoma will NOT be eligible for this study, irrespective of molecular subgroup and extend of local resection Parts A & C: patients must be >= months and < years of age at the time of study enrollment Parts B-B, B, D-D, E, E: patients must be >= months and =< years of age at the time of study enrollment Part B: patients must be >= months and < years of age at the time of study enrollment Eligible Ages in Australia and Canada; years to years Age of years or older; in addition, patients age to years may enroll beginning in Cohort if weight ? kg Patients with body mass index (BMI) < rd percentile for age, as defined by WHO criteria for patients - years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > years of age, are not eligible Participants who are less than years of age at start of maintenance chemotherapy Part A: Patients must be >= months and =< years of age at the time of study enrollment Standard risk : Patient must be < years of age at enrollment Standard risk : Patients must be >= and < years of age at enrollment Hemoglobin >= g/dL for patients =< years of age; >= g/dL for patients > years of age; Note: no transfusions are permitted days prior to laboratory studies to determine eligibility Efficacy Phase: Patients must be =< years of age at the time of enrollment Age ? years (or per national guidelines). Adult patients ? years Subjects must be age ? years at initial diagnosis Subjects must be age ? years at initial diagnosis Adults (Age ? years) Adults age - years years of age or order Subjects ? years of age for solid tumor; in the case of midline carcinoma with NUT rearrangement. subjects may be ? years of age. Patients must fit into one of the following categories:\r\n* Age >= years to < years with a cumulative illness rating scale (CIRS) score >= OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >= years Pts must be ? years of age Must be less than years of age at time of original diagnosis Be between the ages of ? and ? years St. Jude patients must be between years and =< years of age, on therapy (active patient), or within years of completion of therapy; patients treated at collaborating sites must be =< years old Male or female participants age ? years (or any age ? years if that age is considered to be an adult per the local jurisdiction) at the time of informed consent years of age at the time of consenting. Age ? . years and < . years at the time of enrollment. Patients =< years of age will be eligible for the pre-surgical cohort; patients between - years of age will be treated at the adult Food and Drug Administration (FDA)-approved dose of mg BID and can be enrolled immediately; patients less than years of age will be enrolled and treated at the pediatric MTD once it is defined in the safety cohort Patients =< years of age with evaluable disease will be eligible for the expansion cohort; patients between and years of age will take adult dose of mg BID and are eligible at the initiation of the trial; patients less than years of age will take the MTD once it is defined in the safety cohort Must be ? years of age. Due to increased risk of sepsis in patients > years old, candidate patients in this age group should be thoroughly evaluated prior to study randomization to ensure they are fit to receive chemotherapy. In addition to all of the inclusion/exclusion criteria listed, clinical judgment should be used regarding patients' susceptibility to infection (including but not limited to presence of ascites or diabetes mellitus increasing risk of infection). Furthermore, the expected stability of their performance status while receiving repeat weekly chemotherapy cycles should be given special attention. Patients in this age group should not be randomized on the study should there be any hesitation on any of these considerations. Patient is < years of age at time of enrollment. Participants with to less than (<) years of age (Part only), or to years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at < years of age (Part only) Age: ? years at the time of study entry. Age >= years or age of majority at the participating site, whichever is greater Patients must be less than years of age at the time of diagnosis. Age ? years. Because no dosing or adverse event data are currently available on the use of ipilimumab or indoximod in patients < years of age, children are excluded from this study. Age >= year and < years at the time of screening; exception: participants with recurrent, progressive, or refractory medulloblastoma and are >= and < years of age at the time of study screening are eligible for screening STRATUM A: Age >= year and < years at the time of screening STRATUM B: Age >= year and < years at the time of study enrollment STRATUM C: Age >= years and < years at the time of study enrollment Age > years and ? years at the time of enrollment Patient is at least years of age and < years of age at the time Informed Consent is signed. The pediatric cohort is defined as age younger than years. Patients ? years of age at the time of signature of the ICF Age:\r\n* Phase : >= and =< years of age at time of enrollment\r\n* Phase : >= and =< years of age at diagnosis Adults ? years of age Adults ? years of age Patient age criteria: age >= and =< years (myeloablative regimen ; age >= and =< years (nonmyeloablative regimen ) at the discretion of the investigator(s); age >= and =< years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen Appropriate written consent adult or parent/guardian if patient is < years of age and minor information sheet if patient is > years of age Age >= to < years; patients to years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning Age months - . years at enrollment Age (at the time of consent/assent): ? years of age < % for patients < years, Age > years at time of study entry Age < years and at least of the following conditions: Patients must be > than months and ? years of age at the time of study enrollment. Males and females years of age and older; subjects < years of age that meet any of the following criteria: \r\n* Subjects that refuse to be treated with chemotherapy based agents (this should be documented in the consent form)\r\n* Subjects that are not candidates for treatment with chemotherapy agents based on any of the following:\r\n** ECOG performance status >= \r\n** Cumulative illness rating scale (CIRS score) >= \r\n** Creatinine clearance < mL/min using the Cockcroft-Gault equation Age: ? years at the time of diagnosis. Any patient with both metastatic ependymoma and age < years at the time of enrollment Pediatric patients (age - years) will be entered only after adult patients have been entered without dose limiting toxicity Age: up to and including years at diagnosis of Haemophagocytic Lymphohistiocytosis Be between the ages of ? and ? years Age: \r\n* Stratum I (TMI containing arm): - years of age\r\n* Stratum II (non TMI arm): - years of age within the last years OR Postmenopausal defined as women > years of age with amenorrhea for ? years prior to screening > years Age ? years at the time of screening or age of consent according to local law Age years and year or more of amenorrhea Age > years. Because no dosing or adverse event data are currently available on the use of AR- in patients < years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable. Man or woman, age > years Stratum (IDH wild-type): Patients must be >= years of age and =< years of age at the time of enrollment Stratum (IDH mutant): Patients must be >= years of age and =< years of age at the time of enrollment Minimum age years (in Japan, minimum age years). One of the following:\r\n* Age >= years\r\n* Age < years but unsuitable for standard chemotherapy because of a cardiac ejection fraction of < %, a pulmonary diffusion capacity < %, or a creatinine clearance >= and < mL/min, or refused standard chemotherapy despite efforts to convince them otherwise Age (must have body surface area [BSA] >= . m^):\r\n* Phase I: >= and =< years of age\r\n* Phase II: >= and =< years of age > years of age must be approved by principal investigator Minimum Age years (in certain territories, the minimum age requirement may be\n higher eg age years in Japan and Taiwan) Age:\r\n* Part A: Patients must be >= months and < years of age at the time of study enrollment\r\n* Part A: Patients must be > months and < months of age at the time of study enrollment; patients will enroll one dose level behind the dose level at which patients in Part A are enrolling Age:\r\n* Phase (Part A)\r\n** Patients must be > than months and =< years of age at the time of study enrollment\r\n* Phase (Part B and Part C)\r\n** Patients must be > than months and =< years of age at the time of study enrollment Serum estradiol level assay (required for patients < years of age and one year or more of amenorrhea) < pg/mL Age (at the time of consent/assent): ? months to ? years Cohort only: ? years to ? years Age - years; age > allowed at investigator discretion if performance status ? ; and each organ system score ? using cumulative illness rating scale (CIRS) Age ? years or the minimum legal adult age (whichever is greater) at the time of Informed consent. Age < years and > month (< month upon approval by Sponsor) Patients must be > months and < years of age when registered on study. Patients must be > years and < years of age when registered on study. Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >= years; or participants less than (<) years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below years of age is required before randomization Age ? years and one year or more of amenorrhea Age < years and one year or more of amenorrhea, with an estradiol assay < pg/mL Age ? years at the time of screening At least years of age Except: where local regulations and/or institutional policies do not allow for subjects < years of age (pediatric population) to participate. For those sites, the eligible subject population is ? years of age Men and women years of age to years of age of any ethnic origin or race at the time of signing the ICD. Age superior or equal to years or country's legal age of majority if the legal age is superior to years old. Patients must be ? months of age and ? years of age at the time of study entry for patients diagnosed with DIPG. Patients must be ? months of age and ? years of age at the time of study entry for patients diagnosed with HGG. Adult women (? years of age) with advanced TNBC. Male or female, greater than or equal to (>=) years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > years of age); [i.e. >= years of age in Japan]) Patient is at least years of age at randomization. Age ? years (? years in Japan). Cohort patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) .\r\n* Note: patients in Cohort will be stratified as follows:\r\n** Stratum : Patients >= years of age but < years\r\n** Stratum : Patients >= years of age but < years Adults ? years of age. Age years or younger at the time of initial ALL diagnosis and age > year at the time of study treatment initiation. Minimum age in Japan is years. Age >= years and not candidates for conventional cytotoxic chemotherapy or refuse it; OR patients below the age of years who are considered unfit and/or unable to tolerate standard chemotherapy at the discretion of the treating physician or the principal investigator Adult patient, >/= years of age Males and female subjects ? years of age at the time of enrollment, except in Japan where subjects must be ? years of age at the time of enrollment Age - years at the time of diagnosis of AML Subjects younger than years of age Female gender and age ? years at time of study entry F FLT CANDIDATE TRANSPLANT RECIPIENT: Age >= years old at National Cancer Institute (NCI), and age > years and < years at Childrens National Medical Center E . Less than years (or country's legal age of majority if the legal age is > years). Unable to receive intensive chemotherapy regimens at enrollment, based on one of the following: I. Age ? years, or II. Age < years with at least of the following co-morbidities: Age ? years. A patient may be of either sex and of any race/ethnicity. For ESFT patients age ? years. For ESFT patients age ? years. Age ? years (non-ESFT candidates) Age >= years (age > years to participate in optional symptom burden assessment) Minimum age years (in certain territories, the minimum age requirement may be higher (e.g. years in Japan and Taiwan) Patients must be ? and ? years of age when originally diagnosed with ALL. Diagnosis Male or female outpatients (except where inpatient stay is required for medical need at the Investigator's discretion) at least years of age at the time of informed consent Prior radioimmunotherapy within years of enrollment Patients over years of age, regardless of race of gender Patients younger than years of age Adult patients, >/= years of age Adult patients, >/= years of age Patients must be ? years of age at the time of enrollment. At least years of age at time of study entry Adult patient, >/= years of age Adult participants, >/= years of age Adult patients, >/= years of age ? years. Participants must be ? years since no dosing or adverse event data are currently available on the use of OGX- in participants < years of age. Is months (at least weeks gestation) to < years of age Patients must be < years of age when registered on study. For the initial dose escalation to identify the maximum tolerable or PK target dose, age between years and < years (inclusive) at the time of signing the informed consent form. Children < years of age will be enrolled once the age specific expansion cohorts are open. PHASE I: >= years and =< years of age at the time of study enrollment, if able to swallow whole capsules Adults > years of age Adult patients, >/= years of age Patient is ? years of age on the day of consent signature Adults >/= years Participants must be < years of age at the time of study entry\r\n* Participants currently on therapy at St. Jude, or within years of completing therapy at St. Jude must be =< years of age\r\n* Other participants must be =< years of age Patients up to years of age at time of registration with a diagnosis of SAA; SAA is defined as follows: Ages - years, The parent must be at least years of age to ensure the age of majority across all participating sites to legally consent their child to years of age at diagnosis of first cancer Age ? years at the time of screening. The child is - years of age at time of enrollment One parent (? years of age) can be present for all sessions PROVIDER ELIGIBILITY: The participant is greater than years of age Ages - years EXCLUSION FOR PARENTS: Parent is < years of age PHASE A: AYA SURVIVOR ELIGIBILITY: At least years from treatment for any pediatric cancer diagnosed at age - PHASE B: PATIENT ELIGIBILITY: At least years from treatment for any pediatric cancer diagnosed at age - Co-survivors must be over the age of years Qualitative interviews will be conducted in patients (age years or older) with their assent/consent; patients (age -. years) will be asked to complete surveys that have been validated in this age group and that offer insight into the usefulness of the BMT Roadmap; patients ( years or older) will be asked to complete surveys Child: child is age to years, months Age\r\n* For centers that will use fluconazole as the antifungal comparator:\r\n** Age >= months and < years\r\n* For centers that will use voriconazole as the antifungal comparator:\r\n** Age >= years and < years Off treatment > years Is ? years or the minimum legal adult age (whichever is greater) and ? years (at Screening); For dose-escalation stage (tablets): age at study entry >= years to < years For dose-escalation stage (suspension): age at study entry >= months to < years. Participants < year of age will not be enrolled until >= participants >= year to < years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted. For expansion stage: age at study entry to be >= months (>= years if suspension is not available) to < years. Participants >= months to < year of age may not be enrolled until >= participants >= year to < years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted. Age - years at time of study enrollment Bone Mineral Density (BMD) requirements: Osteopenia if under years of age; Osteopenia or normal BMD if over years of age Were diagnosed with a childhood cancer prior to the age of years Have at least relatives with breast cancer on the same side of the family, one of which is =< years of age RECIPIENT: Age to years Age >= years for the feasibility phase; age >= years old AND >= kg for the phase II portion Have smoked for at least years; At time of approach, >= years from initial cancer diagnosis or >= years from first HCT, whichever is later. Adult (? years) Age: - years at the time of diagnosis. Age: - years at the time of diagnosis. Age: - years at the time of diagnosis. Mammogram negative for breast cancer within the months preceding the time of registration for women >= years of age Is (at least weeks gestation) to years of age at time of randomization Between . years and < . years of age at the time of recruitment Age ? years and one year or more of amenorrhea Age < years and one year or more of amenorrhea, with an estradiol assay < pg/ml Adult patients at least years of age Individuals who are less than years of age Signed written informed consent (by parent if patient is < years of age, or by patient, if he or she is >= years of age) Patient assent for those >= years of age and < years of age for whom a parent provides informed consent Male or females with an age ? years (? years in Japan) Adult male >/= years of age Females ? years of age presenting for routine cervical cancer screening. Pediatric patients of any age are eligible, including those that may require sedation for MRI; more specifically, children - years of age and adults >= years of age are eligible Adult patients over years of age; Patients younger than years Age: > month and < years at time of enrollment ? years Age ? years at time of consent ( years if required by local or state laws)